What is Kairos Pharma, Ltd.'s Market Cap?

Kairos Pharma, Ltd.'s Market Cap is $41.7M, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s Enterprise Value?

Kairos Pharma, Ltd.'s Enterprise Value is $39.1M, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s EV / EBITDA?

Kairos Pharma, Ltd.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s Revenue (TTM)?

Kairos Pharma, Ltd.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s Net Income (TTM)?

Kairos Pharma, Ltd.'s Net Income (TTM) is -$5.8M, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s EBITDA?

Kairos Pharma, Ltd.'s EBITDA is -$5.8M, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s Diluted EPS (TTM)?

Kairos Pharma, Ltd.'s Diluted EPS (TTM) is -0.24, based on as-reported figures from SEC (XBRL) filings.

What is Kairos Pharma, Ltd.'s Net Debt?

Kairos Pharma, Ltd.'s Net Debt is -$2.6M, based on as-reported figures from SEC (XBRL) filings.

Kairos Pharma, Ltd. (KAPA) Financial Statements

Kairos Pharma, Ltd.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG01JLR1S38

XASE · usd

1.76▼ 0.01 (-0.56%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close1.77

Day's Range1.77 – 1.89

52-Week Range0.22 – 2.11

Volume172.5K

Avg Volume498.8K

Share Statistics

Shares Outstanding

Employees1

ExchangeXASE

Listed2024-09-16

Share count as of August 12, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Kairos Pharma, Ltd. (KAPA)

What is Kairos Pharma, Ltd.'s Market Cap?: Kairos Pharma, Ltd.'s Market Cap is $41.7M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Enterprise Value?: Kairos Pharma, Ltd.'s Enterprise Value is $39.1M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s EV / EBITDA?: Kairos Pharma, Ltd.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Revenue (TTM)?: Kairos Pharma, Ltd.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Net Income (TTM)?: Kairos Pharma, Ltd.'s Net Income (TTM) is -$5.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s EBITDA?: Kairos Pharma, Ltd.'s EBITDA is -$5.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Diluted EPS (TTM)?: Kairos Pharma, Ltd.'s Diluted EPS (TTM) is -0.24, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Net Debt?: Kairos Pharma, Ltd.'s Net Debt is -$2.6M, based on as-reported figures from SEC (XBRL) filings.